XNASTCBP
Market cap314kUSD
Dec 23, Last price
0.64USD
1D
-3.64%
1Q
-89.94%
IPO
-99.37%
Name
TC BioPharm Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
-100.00%
Net income
-6m
L+349.68%
CFO
-11m
L-31.04%
Profile
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 3,845 94.30% | 1,979 0.00% | |||
Cost of revenue | 14,642 | 16,331 | 9,266 | ||
Unusual Expense (Income) | |||||
NOPBT | (14,642) | (12,486) | (7,287) | ||
NOPBT Margin | |||||
Operating Taxes | (1,089) | 1,720 | 1,408 | ||
Tax Rate | |||||
NOPAT | (13,553) | (14,206) | (8,695) | ||
Net income | (5,907) 349.68% | (1,314) -90.32% | (13,576) 148.74% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 4,187 | ||||
BB yield | -4,275.47% | ||||
| Debt | |||||
Debt current | 305 | 653 | 13,732 | ||
Long-term debt | 4,793 | 3,922 | 5,040 | ||
Deferred revenue | |||||
Other long-term liabilities | (1,496) | 1,866 | |||
Net debt | 2,636 | (233) | 17,205 | ||
| Cash flow | |||||
Cash from operating activities | (10,545) | (15,292) | (5,581) | ||
CAPEX | (110) | (241) | (20) | ||
Cash from investing activities | (209) | (310) | (143) | ||
Cash from financing activities | 8,520 | 18,653 | 6,525 | ||
FCF | (13,940) | (15,743) | (6,731) | ||
| Balance | |||||
Cash | 2,463 | 4,808 | 1,567 | ||
Long term investments | |||||
Excess cash | 2,463 | 4,616 | 1,468 | ||
Stockholders' equity | (38,835) | (32,977) | (16,559) | ||
Invested Capital | 43,322 | 35,759 | 17,735 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 31 | ||||
Price | 3.17 -17.66% | 3.85 | |||
Market cap | 98 | ||||
EV | 2,733 | ||||
EBITDA | (14,009) | (11,527) | (6,278) | ||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||